Position in GELS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$9,141
-$30,996 QoQ
Shares Held
13,830
-40.4% QoQ
Ownership
0.129%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#3
of 5 holders
Holding Since
Dec 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GELS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026CITADEL ADVISORS LLC holds $928,363,116 across 59 Drug Manufacturers - Specialty & Generic names. GELS ranks #58 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
360,643 | $213,854,086 | |
| 2 | INDV |
Indivior Pharmaceuticals, Inc.
|
3,574,044 | $108,936,860 | |
| 3 | ELAN |
Elanco Animal Health Inc
|
4,387,127 | $104,983,948 | |
| 4 | ALKS |
Alkermes plc.
|
2,241,584 | $79,262,409 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
|
1,493,446 | $77,196,223 | |
| 6 | ZTS |
Zoetis Inc.
|
501,011 | $59,224,510 | |
| 7 | VTRS |
Viatris Inc
|
3,993,155 | $53,947,523 | |
| 8 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
474,750 | $22,859,212 |
All Filings in GELS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,141 | 13,830 | Shares | Defined | 2026-05-15 | |
| 2025-06-30 | $40,137 | 23,201 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $15,771 | 15,165 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $55,095 | 23,748 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||